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Introduction
Gastrointestinal stromal tumors (GISTs), which are
regarded as malignant tumors with variable grades of
risk, represent the most common subgroup of
gastrointestinal mesenchymal tumors (GIMTs).
Compared with the stomach and small intestine, the
colon and rectum are rare sites of GIST localization
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(< 5% of cases).1,2 In addition, GISTs account for only
0.1% of all colorectal cancers. For many years, GISTs
were regarded as leiomyomas (LMs); smooth muscle
tumors of uncertain, unknown, or undetermined, ma-
lignant potential (STUMP); leiomyosarcomas (LMSs)
when composed of spindle cells; and as benign or ma-
lignant leiomyoblastomas (or epithelioid LMs or LMSs,
respectively) when composed of epithelioid cells.3,4
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With molecular improvements in several agents
targeting components of pathways and processes
crucial to neoplastic transformation and progression,
molecular-targeted therapy for GISTs has become
possible. Thus, because of the malignant potential of
GISTs and the availability of improved treatments, it
is important to distinguish GISTs from other GIMTs.
The first objective of this retrospective study was to
reclassify colorectal mesenchymal tumors, from files
collected over 20 years, to determine if, based on
immunohistologic features, the lesions were truly
GISTs. The second objective was to identify the
relationship between clinicopathologic features and
prognostic factors of GISTs in the colon and rectum.
Methods
Case histories and follow-up
Cases of mesenchymal tumor involving the colorectum
(coded as LM, LMS, or stromal tumor) were retrieved
from the database of the Department of Surgical
Pathology at Taichung Veterans General Hospital
for the period 1 January 1983 to 31 December 2001.
A total of 27 cases were procured and reviewed.
Excluded from the study were 1 case of perirectal LM
that resembled uterine LM and 1 case of serosal
fibromyoma.
For all patients, clinical data (age and gender),
tumor characteristics (location, gross appearance
[polypoid or intramural], size [maximal diameter in
centimeters]), surgical procedures, and survival
outcomes, were retrospectively obtained from hospital
records and, where possible, confirmed by telephone.
Histologic evaluation
All hematoxylin and eosin-stained slides for each case
were reviewed. The following features were recorded
in all cases: predominant cell type, cellularity, mitotic
count per 10 high-power fields (hpfs), and tumor
hemorrhage and necrosis (unrelated to mucosal
ulceration). The definition of predominant cell type
depended on the percentage of epithelioid tumor cells
present: the presence of more than 50% epithelioid
cells was defined as epithelioid cell type; 10–50% as
mixed; and less than 10% as spindle cell type. Low
cellularity indicated that tumor cells had ample
cytoplasm separating the nuclei. Mitosis was counted
in the most cellular and mitotically active areas for 10
hpfs. Tumor necrosis and hemorrhage that could
easily be seen under low-power microscopy (40×) was
defined as macroscopic. Nuclear pleomorphism that
could be seen under middle-power microscopy (100×)
was defined as high grade, and under high-power
microscopy as low grade.
Immunohistochemistry
The following antibodies were applied to antigens
from a representative sample from each patient: CD117
(DAKO, Copenhagen, Denmark; polyclonal, dilution
1:300), CD34 (DAKO; monoclonal, dilution 1:50),
smooth muscle actin (DAKO; actin M851,
monoclonal, dilution 1:100), desmin (DAKO;
monoclonal, dilution 1:100), neuron-specific enolase
(NSE) (DAKO; monoclonal, dilution 1:200), and S-
100 protein (DAKO; polyclonal, dilution 1:400).
Microwave-based epitope retrieval agent (320 mg
sodium EDTA/L, pH 8.0) was applied before
immunostaining for CD34 and CD117. Immuno-
staining was performed using the avidin biotin
peroxidase complex detection system with
diaminobenzidine as the chromogen. The staining
was interpreted only when internal positive controls
were present (mast cells for CD117, endothelial cells
for CD34, smooth muscle cells for actin M851, and
nerve bundles for NSE and S-100 protein); however,
this rule was not used with desmin because normal
muscle tissue was sometimes absent in the slides. Four
semi-quantifiable scores were used, based on the
percentage of positive tumor cells (0–25%, 1+; 25–
50%, 2+; 50–75%, 3+; and 75–100%, 4+). Two of the
authors evaluated the results, and consensus was
achieved in each case.
Statistical analysis
The relationship between KIT expression and
clinicopathologic features (especially local recurrence,
distant metastasis and lethality) was investigated by
Pearson’s Chi-squared test, Fisher’s exact test,
independent t test, and Mann-Whitney U test (SPSS
for Windows, version 10.1; SPSS Inc, Chicago, IL,
USA). Survival analysis was performed by log-rank
test. A p value of less than 0.05 was considered
statistically significant. Univariate and multivariate
analyses were applied to all data.
Results
Clinical features
The clinical characteristics of the 25 patients are
summarized in Table 1. There were 16 males (64%)
and 9 females (36%), and patient age ranged from 37–
79 years (mean, 59.0 ± 10.7 years). Eighteen patients
had the following symptoms: constipation (n = 6);
palpable mass (6); anal bleeding (3); bloody stools (2);
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diarrhea (2); tenesmus (2); and tarry stools (1). The
most common tumor location was the rectum (n =
20), followed by the colon (5). The mean tumor
maximum diameter was 3.98 ± 3.96 cm (range, 0.2–
12.0 cm). Grossly, the tumors presented as submucosal
polyps (n = 7) or intramural tumors (18). They were
described as having the following consistency: gray-
brown soft (n = 8); gray-tan-brown firm (8); gray soft
(6); yellow-tan-white firm (2), or yellow-brown soft
(1). Focal hemorrhage (n = 3), cystic changes (1) and
necrosis (1) were noted on sectioning.
Treatment and follow-up
Polypoid tumors (n = 7) were typically treated with
polypectomy. The smallest intramural tumors () 2 cm
in diameter) were treated with per-anal excision (n =
5), although enucleation is the traditional treatment.
Of intramural tumors that were larger than 2 cm but
not more than 5 cm in diameter, 4 were treated with
per-anal excision, while segmental resection was
performed in 2 cases. Intramural tumors larger than 5
cm in diameter were commonly treated with segmen-
tal resection (n = 6), whereas per-anal excision was
performed in only 1 case. No patient received post-
operative radiotherapy and/or chemotherapy.
The mean follow-up period was 40.6 ± 38.1 months
(range, 0–158 months). Local recurrence (n = 6)
occurred in 4 patients treated with per-anal excision,
and in 2 treated with segmental resection. In the latter
group, 1 patient had local recurrence and liver metas-
tasis 23 months after segmental resection. He subse-
quently died from his disease without being treated
with imatinib mesylate (STI571; GleevecTM; Novartis
Pharmaceuticals Corp, East Hanover, NJ, USA).
Another patient who had local recurrence 48.5 months
after segmental resection also died from his disease.
Thus, survival analysis revealed that 2 patients died
from colorectal mesenchymal cancer; 3 died from
other diseases (chronic renal failure, cervical cancer,
intracranial hemorrhage); 2 patients with local
recurrence after per-anal excision were alive with
disease; and 18 were alive without disease.
Table 1. Clinical characteristics
Patient
Age
Gender Symptoms
Tumor Gross Tumor
Surgery
Follow-up Local Distant
Outcome
(yr) location features size (cm) (mo) recurrence metastasis
1 79 M No Colon P 0.5 PP 49.0 No No AWOD
2 68 M Yes Colon P 0.4 PP 3.5 No No DFOD
3 56 M No Colon P 0.5 PP 24.5 No No AWOD
4 67 M Yes Colon P 0.2 PP 47.5 No No AWOD
5 47 F No Colon P 1.0 PP 33.0 No No AWOD
6 45 F Yes Rectum I 1.6 PAE 0 No No AWOD
7 70 F No Rectum P 0.6 PP 24.0 No No DFOD
8 66 F Yes Rectum I 1.5 PAE 26.5 Yes No AWOD
9 37 F Yes Rectum I 4.0 PAE 158.0 Yes No AWD
10 64 M Yes Rectum I 5.5 PAE 89.0 No No DFOD
11 61 M Yes Rectum I 4.0 PAE 36.0 Yes No AWD
12 74 F No Rectum I 0.5 PAE 65.0 No No AWOD
13 48 F Yes Rectum I 1.2 PAE 0.25 No No AWOD
14 54 F No Rectum I 2.5 PAE 99.0 No No AWOD
15 62 F Yes Rectum I 1.0 PAE 48.0 No No AWOD
16 50 M No Rectum P 0.3 PP 70.0 No No AWOD
17 65 M Yes Rectum I 4.0 PAE 90.0 Yes No AWOD
18 52 M Yes Rectum I 8.0 SR 37.0 No No AWOD
19 47 M Yes Rectum I 12.0 SR 27.0 No No AWOD
20 42 M Yes Rectum I 11.0 SR 22.0 No No AWOD
21 58 M Yes Rectum I 12.0 SR 23.0 Yes Yes (liver) DFD
22 67 M Yes Rectum I 5.0 SR 0.5 No No AWOD
23 66 M Yes Rectum I 7.7 SR 0.5 No No AWOD
24 67 M Yes Rectum I 10.0 SR 40.5 Yes No DFD
25 62 M Yes Rectum I 4.5 SR 0.5 No No AWOD
AWD = alive with disease; AWOD = alive without disease; DFD = died from disease; DFOD = died from other disease; I = intramural; P = polypoid;
PAE = per-anal excision; PP = polypectomy; SR = segmental resection.
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Microscopic findings
Histopathologic characteristics are summarized in
Table 2. A spindle-cell pattern was seen in most cases
(92%); 2 tumors had mixed spindle and epithelioid
cytology. Over half of all tumors (64%) had high
cellularity.
Mean mitotic count was 2.88 ± 5.04 per hpfs
(range, 0–15 per 10 hpfs). Mitotic count was 1–5 per
10 hpfs in 5 cases (20%); these tumors were originally
diagnosed as LM, smooth muscle tumor (SMT),
STUMP and GISTs (committed and combined type).
In another 5 cases (20%), mitotic count was more than
5 per 10 hpfs; these tumors were originally diagnosed
as LM, LMS and GIST (neural type).
Nuclear atypia was present in 6 tumors (24%): 4 as
high-grade and 2 as low-grade. Six tumors (24%)
showed hemorrhage on sectioning, 3 of which were
microscopic foci. Coagulation necrosis was seen in 5
cases (20%): it was macroscopic in 3 cases and
microscopic in 2. Most of the cases with hemorrhage
and necrosis represented large and mitotically active
tumors.
Histologic examination of tumor extension into the
peripheral surgical margin was observed in 4 of 10 per-
anal excision specimens, and 2 of 8 segmental excision
specimens. Skeinoid fibers and focal calcification were
not seen in all cases. No lymph node metastasis was
detected in 6 patients treated with segmental resection
(average of 5 nodes studied from each).
Immunohistochemical findings
Immunohistochemical findings are summarized in
Table 2. CD117 (KIT)-immunoreactivity was
identified in 18 of 25 cases (72%) by diffuse membrane
and cytoplasmic staining in * 50% of tumor cells.
CD34-positivity was seen in all these cases, with only
1 case having ) 25% of tumor cells positive. An
immunonegative result for both actin M851 and
desmin was documented in 2 tumors, and for both
NSE and S-100 in 1 tumor. Immunohistochemistry
showed negative CD117 staining for 7 polypoid
tumors, which were immunopositive for actin M851
and desmin, but immunonegative for CD34, NSE,
and S-100 protein.
Table 2. Histopathologic and immunohistochemical characteristics
Patient Cell type Cellularity
Mitoses Nuclear
Hemorrhage Necrosis CD117* CD34*
Actin
Desmin* NSE* S-100*
per 10 hpf atypia (grade) M851*
1 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
2 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
3 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
4 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
5 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
6 Spindle High 0 No No No 4+ 4+ 1+ 1+ 2+ 1+
7 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
8 Spindle High 0 Low No No 2+ 4+ 2+ 3+ 3+ 1+
9 Spindle High 4 No No No 4+ 4+ 1+ 1+ 1+ 1+
10 Spindle High 2 No MA No 4+ 4+ 1+ 2+ 3+ 1+
11 Spindle High 2 No No No 4+ 4+ 1+ 1+ 1+ 1+
12 Spindle High 0 No No No 4+ 4+ 3+ 2+ 1+ 2+
13 Spindle High 0 No No No 3+ 4+ 1+ 1+ 1+ 1+
14 Spindle High 0 No No No 4+ 4+ 3+ 1+ 0 1+
15 Spindle Low 0 No No No 3+ 4+ 3+ 1+ 0 0
16 Spindle Low 0 No No No 0 0 4+ 4+ 0 0
17 Mixed High 9 High No No 3+ 4+ 0 0 3+ 1+
18 Mixed High 1 No MI MA 3+ 1+ 2+ 1+ 1+ 1+
19 Spindle High 1 No No No 3+ 4+ 1+ 1+ 0 1+
20 Spindle High 0 No No No 4+ 4+ 1+ 1+ 2+ 2+
21 Spindle High 14 High MA MA 2+ 4+ 0 0 2+ 1+
22 Spindle High 15 High MA MA 4+ 4+ 4+ 0 4+ 2+
23 Spindle High 13 Low MI MI 4+ 4+ 1+ 0 4+ 2+
24 Spindle High 11 High MI MI 4+ 4+ 3+ 1+ 1+ 1+
25 Spindle Low 0 No No No 4+ 4+ 1+ 1+ 2+ 1+
*Scores are based on the percentage of positive tumor cells: 1+ = 0–25%; 2+ = 25–50%; 3+ = 50–75%; 4+ = 75–100%.
hpf = high-power field; MA = macroscopic; MI = microscopic; Mixed = mixed spindle and epithelial; NSE = neuron-specific enolase.
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Statistical evaluation
The relationship between KIT expression and
clinicopathologic features is summarized in Table 3.
The following variables were significantly associated
with different CD117 results from Fisher’s exact test:
symptomatic presentation (p = 0.007); tumor location
(p < 0.001); gross features (p < 0.001); cellularity
(p < 0.001); and type of surgery (p < 0.001). In
addition, significant relationships were identified by
the Mann-Whitney U test between CD117 status and
tumor size (p < 0.001), and between CD117 status
and mitotic count (p = 0.034).
Seven patients had CD117-negative tumors: all ex-
cept 2 (1 with tarry stools and diarrhea, 1 with bloody
stools) were asymptomatic (71.4%). Tumors showed
polypoid gross features (100%), small size (0.50 ±
0.10 cm), low cellularity (100%), and a 0 mitotic count
per 10 hpfs (100%). After polypectomy, no malignant
behavior (local recurrence, distant metastasis, lethality)
occurred during follow-up (35.9 ± 21.6 months).
Table 3. Relationship between KIT expression and clinicopathologic features
CD117-positive (n = 18) CD117-negative (n = 7) p
Symptoms 0.007
No 2 5
Yes 16 2
Location < 0.001
Colon 0 5
Rectum 18 2
Gross features < 0.001
Polypoid 0 7
Intramural 18 0
Size, cm (mean ± SD) 5.55 ± 0.88 0.50 ± 0.10 < 0.001
Mitoses/10 hpf (mean ± SD) 4.00 ± 1.32 0 0.034
Cellularity < 0.001
Low 2 7
High 16 0
Nuclear atypia 0.137
No 12 7
Yes 6 0
Hemorrhage 0.137
No 12 7
Yes 6 0
Necrosis 0.274
No 13 7
Yes 5 0
Surgery < 0.001
Polypectomy 0 7
PAE or SR 18 0
Local recurrence 0.137
No 12 7
Yes 6 0
hpf = high-power field; PAE = per-anal excision; SD = standard deviation; SR = segmental resection.
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Most of our cases (n = 18) were diagnosed as
GISTs based on combined histopathologic evaluation
and immunohistochemical findings through
identification of the CD117 marker. By univariate
analysis (Pearson’s Chi-squared test), the following
clinicopathologic variables were significantly associated
with increased lethality: tumor size (p = 0.049); mitotic
count (p = 0.019); nuclear atypia (p = 0.019); and
tumor necrosis (p = 0.045). In the survival analysis, a
significant result was obtained for mitotic activity
(cut-off value, 10 mitoses per 10 hpfs) (p = 0.0304;
log-rank test). Using Pearson’s Chi-squared test,
nuclear atypia was associated, but not significantly,
with increased local recurrence (p = 0.087); tumor
necrosis (p = 0.071) and hemorrhage (p = 0.071) were
associated, but not significantly, with increased
metastasis. No appropriate interpretation of results
could be obtained from multivariate analysis.
Discussion
Most gastrointestinal mesenchymal neoplasms,
previously classified as LMs, schwannomas,
leiomyoblastomas, or LMSs, are today classified as
GISTs based on molecular and immunohistologic
features.5 GISTs with a c-kit proto-oncogene mutation
are characterized by over-expression of the KIT protein,
a transmembrane tyrosine kinase receptor for stem-
cell factors.
By histopathologic evaluation and CD117 posi-
tivity, 2 clinicopathologically different categories
could be identified from our colorectal mesenchymal
tumors. The 7 CD117-negative cases (1 had originally
been diagnosed as GIST, and 6 as LM) were gross
intraluminal polyps, and were less symptomatic than
the CD117-positive cases. They had smaller average
size (0.5 cm), lower mitotic count and cellularity than
the CD117-positive cases, and showed only smooth
muscle differentiation immunohistochemically. After
polypectomy, no malignant behavior (local recurrence,
distant metastasis, lethality) was found in these cases.
Similar cases in the study of Miettinen et al6 were
regarded as submucosal LMs arising from the
muscularis mucosae.
The 18 CD117-positive cases in our study (3
tumors had originally been diagnosed as LMS, 1 as
SMT, 1 as STUMP, 9 as LM, and 4 as GIST) were
gross intramural masses, and were frequently
symptomatic. Compared with the CD117-negative
cases, they were located in the rectum, and had larger
tumor size, higher cellularity, higher mitotic count,
and necrosis and hemorrhage, and showed diverse
smooth muscle and neural  di f ferentiat ion
immunohistochemically. They were treated with per-
anal excision or segmental resection, and 6 of them
had malignant behavior (recurrence, metastasis,
lethality). They were regarded as true GISTs,
originating from Cajal cells around the myenteric
plexus in the muscularis propria.
In another study by Miettinen et al,7 most rectal
stromal tumors were GISTs, which had a spectrum
ranging from minimal indolent tumors to overt
sarcomas. Furthermore, LMs of the muscularis
mucosae were more common than GISTs in the
colon, but as common as, or less frequent than,
GISTs in the rectum.8,9 These findings were similar to
those in our study.
However, some tumors have typical clinico-
pathologic and cytogenetic features of GIST, but
do not express detectable KIT protein.10 Recently, a
subset of GISTs was found to have platelet-derived
growth factor receptor (PDGFR) _ gene mutation
rather than c-kit receptor tyrosine kinase (KIT)
mutation.11,12 Thus, for now, GISTs have proved to
have KIT or PDGFR _ mutations. The PDGFR _
gene and KIT gene are adjacent on human chromosome
4, and there is high amino-acid similarity between
them.11 West et al13 generated an antiserum against 1
GIST-specific gene, which was named “discovered on
GIST 1” (DOG1). It encodes for the hypothetical
protein FLJ10261. DOG1 is highly expressed, not
only in typical GISTs, but also in KIT-mutation-
negative GISTs.
In our 18 cases of GIST, both the univariate and
survival analyses revealed that mitotic count was a
statistically significant predictor of lethality. Indeed, a
high mitotic count has generally been accepted as the
best indicator of malignancy in GIST.14,15 In the study
by Rodolico et al,16 a cut-off point of 5 mitoses per 10
hpfs appeared to show a significant level of dis-
crimination between benign and malignant clinical
behavior. In addition, Emile et al17 mentioned that
mitotic activity was the only independent predictive
factor of metastases identified in multivariate analysis
(p < 0.001).
Tumor size, tumor necrosis and nuclear atypia
were also significant predictors of lethality in the uni-
variate, but not in the survival, analysis in our study. In
other studies, tumor size and mitotic count were the
most reliable predictors of outcome,9 and most rectal
GISTs larger than 5 cm in size, or with more than 5
mitoses per 50 hpfs, behaved aggressively.8 In the
latter study, tumor necrosis and nuclear atypia were
seen in 40 cases (30%), most of which were large and
mitotically active tumors.8 Large tumor size and
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high mitotic count are common findings in high-
grade gastrointestinal sarcoma and suggest a poor
prognosis.
Rodolico et al16 showed that neural phenotype was
associated with a tendency towards slightly improved
survival. However, our results indicated no significant
influence on survival after GIST differentiation to
nerve or smooth muscle. Moreover, because the p16
locus is consistently involved in chromosomal losses
found in malignant GISTs, p16 immunohistochemical
assessment seems a promising method for determining
GIST prognosis.18
Snare polypectomy is an adequate treatment for
submucosal LM, but complete tumor removal and
follow-up are necessary for any tumors with atypia or
mitotic activity.6 The rarity of colorectal GISTs, and a
scarcity of patients undergoing long-term follow-up,
make it difficult to determine the proper extent of
surgical resection for this disease. The most highly
recommended approach has been complete
(abdominoperineal or segmental) resection to avoid
tumor rupture and prevent the high frequency of local
recurrence after local excision. In Walsh and Mann’s
series19 of 18 intramuscular anorectal GISTs, 6 of 10
tumors treated with local excision recurred, whereas 0
of 8 tumors treated with abdominoperineal resection
recurred. Thus, the authors pointed out the failure of
local excision to control local spread.
In our study, 4 of 10 per-anal excision cases recurred,
and 2 of 8 segmental resection cases also showed local
recurrence and lethality; thus, no significant difference
existed between the mode of operation and prognosis.
Because the latter 2 cases of segmental resection were
high-risk GISTs (> 10 cm in size; mitotic count > 10
per 10 hpfs), surgical treatment alone was probably
inadequate for disease control. The segmental
resections in our study may also have been incomplete.
A prospective clinical trial may be needed to further
define the appropriate treatment for GISTs.
Mutant isoforms of the KIT or PDGF receptors
expressed by GISTs are considered the therapeutic
targets for imatinib, which is a specific inhibitor of
such tyrosine kinase receptors.20 Phase I–III clinical
trials demonstrated the efficacy of imatinib in the
treatment of metastatic GISTs,21 and it is possible that
the adjuvant and neoadjuvant use of imatinib in the
overall management of advanced GISTs may facilitate
surgeons’ success.22 Hiramatsu et al23 reported the
case of a patient with huge gastric GIST who underwent
effective neoadjuvant therapy with imatinib followed
by surgical resection.
In conclusion, 2 clinicopathologically different
categories, intramural GISTs and polypoid submucosal
LMs, could be identified from our colorectal
mesenchymal tumors; however, future molecular
genetic studies are recommended to prove a lack of
PDGFR _ or KIT gene mutation in these polypoid
submucosal LMs. Our study suggests that, because of
malignant potential, GIST is a better categorization
than SMT. Prognosis is strictly related to the number
of mitoses. Larger patient numbers are needed to
evaluate the prognostic significance of tumor size,
nuclear atypia and tumor necrosis. At present, surgery
is the standard treatment for primary operable GISTs,
and radical surgical removal provides the only chance
for long-term survival.22 Although molecular-targeted
therapy (imatinib) has demonstrated efficacy in the
treatment of unresectable and metastatic GISTs, some
studies have shown that GISTs can develop resistance
to imatinib;24 thus, additional therapeutic strategies
are needed.
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